Citigroup Inc Procept Bio Robotics Corp Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Citigroup Inc holds 36,076 shares of PRCT stock, worth $3.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,076

Previous 13,593 165.4%

Holding current value

$3.51 Million

Previous $830,000 248.19%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$56.31 - $84.99 $1.27 Million - $1.91 Million	22,483 Added 165.4%	36,076 $2.89 Million
Q2 2024 Aug 12, 2024	BUY	$45.73 - $69.19 $125,757 - $190,272	2,750 Added 25.36%	13,593 $830,000
Q1 2024 May 10, 2024	BUY	$40.38 - $50.75 $39,249 - $49,329	972 Added 9.85%	10,843 $535,000
Q4 2023 Feb 09, 2024	BUY	$24.89 - $43.41 $98,415 - $171,643	3,954 Added 66.82%	9,871 $413,000
Q3 2023 Nov 09, 2023	SELL	$30.02 - $38.81 $443,485 - $573,340	-14,773 Reduced 71.4%	5,917 $194,000
Q2 2023 Aug 10, 2023	BUY	$26.7 - $37.02 $368,273 - $510,616	13,793 Added 199.99%	20,690 $731,000
Q1 2023 May 11, 2023	BUY	$26.64 - $39.74 $43,796 - $65,332	1,644 Added 31.3%	6,897 $195,000
Q4 2022 Feb 09, 2023	SELL	$38.78 - $46.78 $59,449 - $71,713	-1,533 Reduced 22.59%	5,253 $218,000
Q3 2022 Nov 10, 2022	BUY	$30.9 - $50.65 $108,150 - $177,275	3,500 Added 106.51%	6,786 $281,000
Q2 2022 Aug 10, 2022	BUY	$29.23 - $44.45 $85,614 - $130,194	2,929 Added 820.45%	3,286 $107,000
Q1 2022 May 12, 2022	SELL	$16.89 - $35.74 $26,399 - $55,861	-1,563 Reduced 81.41%	357 $12,000
Q4 2021 Feb 10, 2022	BUY	$24.6 - $46.29 $47,232 - $88,876	1,920 New	1,920 $48,000

Others Institutions Holding PRCT

# of Institutions

267

Shares Held

38M

Call Options Held

262K

Put Options Held

257K

View Full List

About PROCEPT BioRobotics Corp

Ticker PRCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 44,592,300
Market Cap $4.34B
Description
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...

More about PRCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account